Your shopping cart is empty!
Bexsero Meningococcal Group B Vaccine x 1
Despite successful vaccine production for serogroups A, C, W-135 and Y, MenB has remained an elusive target for immunisation. The vaccine needs to be able to protect against a broad range of MenB strains, and provide immunity in infants, the group most at risk of MenB. 1
The following vaccine types have limitations for vaccination against MenB:
To overcome such problems, Bexsero was developed using a genome-based approach, known as reverse vaccinology.
1. Perrett KP & Pollard AJ. Expert Opin Biol Ther 2005; 5(12): 1611-1625